On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Sunday, March 11, 2012

Standardized study data for electronic submission - CDISC compliance

›
FDA has recently issued a series of draft guidance on “providing regulatory submission in electronic format”. The most recent one is about “...
2 comments:
Friday, March 09, 2012

Futility Analysis in Clinical Trials - Stop the trial for futility

›
A colleague of mine asked me to explain the concept of “futility analysis” using plain languages. The question is triggered by the recent n...
9 comments:
Sunday, February 12, 2012

How to interpret odds ratios that are smaller than 1?

›
Here is a question posted on the web about the interpretation of odds ratios that are less than 1. "I know that OR estimates= 1 mean th...
40 comments:
Sunday, February 05, 2012

Design and Analysis of Bioequivalence Studies for Highly Variable Drugs (HVD) or Highly Variable Drug Products (HVDP)

›
For bioequivalence studies, it is often for us to show the average bioequivalence by declaring the bioequivalence if the 90% confidence int...
1 comment:
Saturday, January 28, 2012

Recording the outcome for AE/SAE when multiple events contribute to Death

›
In clinical trials, death event may occur. According to CDISC CDASH standards , death should not be recorded as an adverse event (AE) or s...
Friday, December 02, 2011

Serious Adverse Events (SAE) vs Severe Adverse Events

›
Professionals who are new to the clinical trial field are often confused with the concept of ' Serious Adverse Events (SAEs)' and ...
Sunday, November 27, 2011

Reporting/recording the Serious Adverse Events (SAE) vs. Adverse Event (AE) Outcomes

›
In clinical trials, the serious adverse event reporting is critical to the safety assessment and to fulfill the regulatory requirements. The...
1 comment:
Thursday, November 24, 2011

Studentized residual for detecting outliers

›
Last time, I discussed the outliers and a simple approach of Dixon’s Q test for detecting a single outlier . When there are multiple outlier...
Saturday, November 12, 2011

Outliers in clinical trial, Dixon's Q test for a single outlier

›
In clinical trials, we deal with the outlier issue differently from other fields. During the clinical trial, for the suspected ‘outlier...
Saturday, October 29, 2011

Story of Xigris (Protein C) for Sepsis

›
Xigris , also called Drotrecogin Alfa (Activated) or Protein C, was the only approved drug for severe sepsis indication and it was withdraw...
Thursday, October 27, 2011

A medical joke to share

›
Not sure where the origin is. It is circulated quite a bit.  Best friends graduated from medical school at the same time and decided that, ...
1 comment:
Saturday, October 15, 2011

Will Electronic Data Capture be always better than Paper-CRF?

›
The traditional way to do the clinical trial data management is to use the paper based case report forms (CRFs). The blank paper CRFs are di...
Tuesday, September 13, 2011

Confidence Interval for Difference in Two Proportions

›
In many clinical trials, the outcome is binomial and a 2 x 2 table can be constructed. The analysis can be based on the difference in two ...
1 comment:
Friday, September 09, 2011

Is it time to change the clinical monitoring practice in clinical trials?

›
In industry, the current monitoring practice relies on ‘ on-site monitoring ’ and 100% source data verification (on all data fields). This ...
2 comments:
Sunday, August 21, 2011

Odds ratio and risk ratio in clinical trials #2

›
In my previous article, I discussed the odds ratio and risk ratio (or relative risk ratio) . In clinical trials with binary outcome, both ...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.